Sign in / Join Now
ETFs & Funds
disagrees with FDA, and decides they will continue with 306 study on its own terms. Not a sound business model...
bit oversimplified what you write there.
Add a reply...
Latest StockTalks »
people get EXEL breaking news and analysis by email alert.
Get email alerts on EXEL »
Get latest price
From other sites
Exelixis To Release Third Quarter 2016 Financial Results On Thursday, November 3, 2016
at TheStreet (Thu, 4:21PM)
Interesting EXEL Put And Call Options For January 2019
at Nasdaq.com (Mon, 11:25AM)
Exelixis Announces Positive Results From Phase 2 CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma Presented At ESMO 2016
at TheStreet (Oct 10, 2016)
Exelixis Reports Genitourinary Results (EXEL)
at Investopedia (Oct 7, 2016)
Exelixis Announces Genentech Presentation Of Preliminary Phase 1b Results For The Combination Of Cobimetinib, Vemurafenib And Atezolizumab At ESMO 2016 Congress
at TheStreet (Oct 7, 2016)